Table 4

Treatment-related adverse events (more than 5% in either group)

Donepezil
(n=72)
Placebo
(n=73)
Visual hallucinations39(54.2)36(49.3)
Auditory hallucinations*8(11.1)26(35.6)
Hallucinations, unspecified8(11.1)7(9.6)
Delusions21(29.2)19(26.0)
Cenesthopathy2(2.8)4(5.5)
Nasopharyngitis*15(20.8)20(38.4)
Parkinsonism (worsening)12(16.7)6(8.2)
Dyskinesias6(8.3)2(2.7)
Dystonia4(5.6)1(1.4)
Contusion9(12.5)8(11.0)
Fall3(4.2)4(5.5)
Vomiting5(6.9)4(5.5)
Nausea5(6.9)2(2.7)
Loss of appetite6(8.3)1(1.4)
Diarrhoea4(5.6)2(2.7)
Loose stool4(5.6)0(0)
Body weight loss4(5.6)0(0)
Urinary cystitis8(11.1)13(17.8)
Dental caries5(6.9)4(5.5)
Back pain4(5.6)7(9.6)
Limb pain4(5.6)2(2.7)
Headache6(8.3)1(1.4)
Upper respiratory tract infection5(6.9)4(5.5)
Aspiration pneumonia0(0.0)5(6.8)
Insomnia5(6.9)5(6.8)
  • The number of adverse events: number of events/patients(%).

  • *There were statistically significant differences in the prevalence of auditory hallucinations (p=0.00007) and nasopharyngitis (p=0.0287).